← Browse by Condition
Medical Condition

non hodgkin lymphoma b cell

Total Trials
3
Recruiting Now
3
Trial Phases
EARLY_Phase 1, Phase 4

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — non hodgkin lymphoma b cell Clinical Trials

How many clinical trials are currently recruiting for non hodgkin lymphoma b cell?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for non hodgkin lymphoma b cell, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for non hodgkin lymphoma b cell?
non hodgkin lymphoma b cell research spans Phase 1 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a non hodgkin lymphoma b cell clinical trial?
Eligibility criteria for non hodgkin lymphoma b cell trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 4
1
Top Sponsors
Zhejiang University 1 trial
Fondazione Italiana Linfomi - ETS 1 trial
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 1 trial

Recruiting Clinical Trials

NCT06716164 EARLY_Phase 1
Recruiting
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
Enrollment
36 pts
Location
China
Sponsor
Zhejiang University
View Trial →
NCT06156774
Recruiting
SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
Enrollment
130 pts
Location
Italy
Sponsor
Fondazione Italiana Linfomi - ...
View Trial →
NCT05518383 Phase 4
Recruiting
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
Enrollment
300 pts
Location
Russia
Sponsor
Federal Research Institute of ...
View Trial →

Related Conditions

burkitt lymphoma (1) primary mediastinal lymphoma (1) primary cns lymphoma (1) diffuse large b cell lymphoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology